101 related articles for article (PubMed ID: 28628491)
1. Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway.
Lv Y; Liu R; Xie S; Zheng X; Mao J; Cai Y; Chen W
Anticancer Drugs; 2017 Sep; 28(8):861-868. PubMed ID: 28628491
[TBL] [Abstract][Full Text] [Related]
2. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
3. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
6. Unfolded Protein Response Promotes Doxorubicin-Induced Nonsmall Cell Lung Cancer Cells Apoptosis via the mTOR Pathway Inhibition.
Zhao X; Yang Y; Yao F; Xiao B; Cheng Y; Feng C; Duan C; Zhang C; Liu Y; Li H; Xiao B; Dai R
Cancer Biother Radiopharm; 2016 Dec; 31(10):347-351. PubMed ID: 27898232
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y; Yan X; Zhang G; Zhao W; Jiao S
Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
[TBL] [Abstract][Full Text] [Related]
8. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Rathos MJ; Khanwalkar H; Joshi K; Manohar SM; Joshi KS
BMC Cancer; 2013 Jan; 13():29. PubMed ID: 23343191
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.
Liu K; Lin FT; Graves JD; Lee YJ; Lin WC
Proc Natl Acad Sci U S A; 2017 May; 114(19):E3766-E3775. PubMed ID: 28439015
[TBL] [Abstract][Full Text] [Related]
11. Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy.
Chowdhury P; Lin GE; Liu K; Song Y; Lin FT; Lin WC
Nat Commun; 2014 Nov; 5():5476. PubMed ID: 25400145
[TBL] [Abstract][Full Text] [Related]
12. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
13. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
Zhu K; Fang W; Chen Y; Lin S; Chen X
Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
[TBL] [Abstract][Full Text] [Related]
14. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Nenkov M; Ma Y; Haase D; Zhou Z; Li Y; Petersen I; Lu G; Chen Y
Oncol Rep; 2020 Jun; 43(6):2073-2082. PubMed ID: 32186773
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
18. ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response.
Nikolos F; Thomas C; Bado I; Gustafsson JÅ
Mol Cancer Res; 2018 Feb; 16(2):233-242. PubMed ID: 29117942
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours.
Jonsson B; Liminga G; Csoka K; Fridborg H; Dhar S; Nygren P; Larsson R
Eur J Cancer; 1996 May; 32A(5):883-7. PubMed ID: 9081371
[TBL] [Abstract][Full Text] [Related]
20. Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer.
Zhao Z; Zheng N; Wang L; Hou Y; Zhou X; Wang Z
Oncotarget; 2017 Jan; 8(5):7827-7838. PubMed ID: 27999199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
